hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06380946 id: 978/91 briefTitle: Influence of Injectable Platelet Rich Fibrin on Different Orthodontic Tooth Movements During Clear Aligner Therapy overallStatus: ENROLLING_BY_INVITATION date: 2024-06-01 date: 2024-10-01 date: 2024-11-01 date: 2024-04-24 date: 2024-04-24 name: Al-Azhar University class: OTHER briefSummary: The aim of this prospective clinical project will be to assess the effect of platelet rich fibrin on the rate of different orthodontic tooth movements during clear aligner therapy. conditions: Effect of Platelet Rich FibrinDuring Clear Aligner Therapy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: BASIC_SCIENCE masking: NONE count: 78 type: ESTIMATED name: iPRF measure: Influence of injectable platelet rich fibrin rate of different orthodontic tooth movements by millimeter sex: ALL minimumAge: 15 Years maximumAge: 22 Years stdAges: CHILD stdAges: ADULT facility: AlAzhar university city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06380933 id: B11103008 briefTitle: The Effects of Receiving Warm Footbath With Lavender Essential Oil on Sleep and Comfort overallStatus: COMPLETED date: 2022-09-01 date: 2022-09-01 date: 2024-02-28 date: 2024-04-24 date: 2024-04-24 name: Dalin Tzu Chi General Hospital class: OTHER briefSummary: Purposes: Describe the background information and clinical characteristics of respirator-dependent patients, verify the sleep and comfort effects of respirator-dependent patients whether or not they receive a lavender essential oil warm water foot bath, and compare changes of the sleep, comfort, heartbeat, and blood pressure in respirator-dependent patients before and after receiving a lavender essential oil warm water foot bath. conditions: Sleep Quality conditions: Comfort studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: two-group crossover design trial and block randomly assigns groups after gender stratification. The experimental group first received a foot bath with lavender essential oil at 41-42C warm water for 20 minutes for 3 days, then rested for 3 days, and then received routine care for 3 days; the control group first received routine care for 3 days, then rested for 3 days, and then received lavender essential oil 41-42C warm water foot bath for 20 minutes for 3 days. primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 94 type: ACTUAL name: experimental group measure: Richards-Campbell Sleep Questionnaire measure: Numerical Rating of Comfort sex: ALL minimumAge: 45 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hsu Mei-Lian city: Chiayi City country: Taiwan lat: 23.47917 lon: 120.44889 hasResults: False
nctId: NCT06380920 id: Digital Health App briefTitle: Function Definition and Clinical Validation of Digital Health App: Using Weight Management as An Example overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2024-12-31 date: 2024-12-31 date: 2024-04-24 date: 2024-04-25 name: National Cheng-Kung University Hospital class: OTHER briefSummary: This project anticipates addressing the obesity epidemics problem which has caused unhealthy lifestyle in billions of obesities and overweight people worldwide. The investigators propose on digital health solution in providing healthcare-on-demand, for personalized health, healthy lifestyle and weight management. This study proposes on using Cognitive Behavior Therapy (CBT) in decreasing individual's food craving, which is administered through AI (Assistive Intelligence) tracking. As with any new medicine, uncertain long-term effects and high costs of these new drugs are also critical factors considered by physicians and policy makers worldwide. Researchers have also reported on 85% of people re-gaining premedication weight after 5 years. There is no easily available self-controlled monitoring strategy/intervention for the unhealthy lifestyle is believed to be one of the main problems. Therefore, the investigators propose on the research and development of self-managing digital health APP (application) for 12 months over two phases, with three months to design APP and nine months to confirm the clinical validation. During the first phase, the investigators propose on design of an "AI Mindful Eating" App, to enhance individual's healthy lifestyle with subsequent weight-loss. Based on "gut-brain-axis", this is anticipated to be achieved by using CBT and AI is used to recognize nutrition and mood within mobile images. This facilitates fulfilling lifestyle and long-term weight-loss. Finally, the study proposes to complete function definition and clinical validation for our AI Humanity APP. By scheduled check-up program by monitoring and analyzing body weight, body fat, anthropometric and metabolic change data between case and control groups. The investigators intend to disclose the effect of the AI assistant APP in weight management and metabolic disease prevention. conditions: Weight Loss conditions: Body Fat Rate Loss conditions: Body Composition Change studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: "AI Mindful Eating" App name: Outpatient regular follow-up measure: weight change measure: Parameters of Metabolic syndrome sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06380907 id: ZL-1102-002 briefTitle: A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-02-28 date: 2026-03 date: 2024-04-24 date: 2024-04-26 name: Zai Lab (Hong Kong), Ltd. class: INDUSTRY name: Zai Lab (US) LLC briefSummary: A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis conditions: Plaque Psoriasis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 250 type: ESTIMATED name: ZL-1102 1% w/w gel BID for 16 weeks name: ZL-1102 3% w/w gel BID for 16 weeks name: ZL-1102 3% w/w gel QD for 16 weeks name: Placebo ZL-1102 0% w/w gel BID for 16 weeks name: Placebo ZL-1102 0% w/w gel QD for 16 weeks measure: Efficacy of different doses of ZL-1102 compared to Vehicle at Week 16. measure: The proportion of patients achieving IGA treatment success. measure: The proportion of patients achieving IGA score of 0 or 1. measure: The percent change from baseline in mPASI score. measure: The proportion of patients achieving mPASI 75 at Week 2, 4, 8, 12, and 20. measure: The proportion of patients achieving mPASI 50/90/100 at Weeks 2, 4, 8, 12, 16, and 20. measure: Time to achieve mPASI 50/75/90. measure: Time to achieve IGA score of 0 or 1. measure: Time to achieve 1- or 2-point improvement in IGA. measure: Incidence of Treatment Related Adverse Events through Week 20. measure: Mean local tolerability scores (LTS) measure: Serum concentration of ZL-1102. measure: Anti-drug antibody (ADA) of ZL-1102. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zai Lab Site 5013 city: Phillip state: Australian Capital Territory zip: 2606 country: Australia lat: -31.13333 lon: 150.85 facility: Zai Lab Site 5016 city: Kotara state: New South Wales zip: 2289 country: Australia lat: -32.95 lon: 151.68333 facility: Zai Lab Site 5017 city: Woolloongabba state: Queensland zip: 4102 country: Australia lat: -27.48855 lon: 153.03655 facility: Zai Lab Site 5014 city: Carlton state: Victoria zip: 3053 country: Australia lat: -37.8 lon: 144.96667 facility: Zai Lab Site 5002 city: Melbourne E. state: Victoria country: Australia lat: -37.81667 lon: 144.9879 facility: Zai Lab Site 5015 city: Melbourne state: Victoria zip: 3124 country: Australia lat: -37.814 lon: 144.96332 hasResults: False
nctId: NCT06380894 id: 2020/2239 briefTitle: Virtual Reality Cognitive Training for Mild Cognitive Impairment overallStatus: COMPLETED date: 2021-01-27 date: 2022-09-30 date: 2023-01-31 date: 2024-04-24 date: 2024-04-24 name: Changi General Hospital class: OTHER briefSummary: This study aims to assess the feasibility and efficacy of a 10-weekly multi-domain VRCT program on the cognitive function (i.e. attention, memory, and executive functioning) of older adults with MCI. conditions: Mild Cognitive Impairment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 20 type: ACTUAL name: Virtual Reality Cognitive Training name: Active Control measure: Change from Baseline in Memory Performance on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) subtests at Week 11 measure: Change from Baseline in Attention Performance on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) subtest at Week 11 measure: Change from Baseline in Attention Performance on the Colour Trails Test 1 at Week 11 measure: Change from Baseline in Executive Function Performance on the Frontal Assessment Battery (FAB) at Week 11 measure: Change from Baseline in Executive Function Performance on the Colour Trails Test 2 at Week 11 sex: ALL minimumAge: 65 Years maximumAge: 85 Years stdAges: OLDER_ADULT facility: Changi General Hospital city: Singapore country: Singapore lat: 1.28967 lon: 103.85007 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2021-01-27 uploadDate: 2024-04-15T09:12 filename: Prot_SAP_000.pdf size: 384298 hasResults: False
nctId: NCT06380881 id: SHR-2017-102 briefTitle: PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-05 date: 2025-07 date: 2024-04-24 date: 2024-04-24 name: Suzhou Suncadia Biopharmaceuticals Co., Ltd. class: INDUSTRY briefSummary: To evaluate the pharmacokinetic characteristics, pharmacodynamic characteristics, safety, tolerability and immunogenicity of SHR-2017 injection in patients with bone metastases, and to evaluate the efficacy of SHR-2017 injection in the treatment of skeletal-related event and cancer pain. conditions: Patients With Bone Metastases studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: SHR-2017 measure: The Pharmacokinetic parameters of SHR-2017 after administration, including Cmax measure: The Pharmacokinetic parameters of SHR-2017 after administration, including Tmax measure: The Pharmacokinetic parameters of SHR-2017 after administration, including AUC0-t measure: The Pharmacokinetic parameters of SHR-2017 after administration, including AUC0-∞ measure: The Pharmacokinetic parameters of SHR-2017 after administration, including t1/2 measure: The Pharmacokinetic parameters of SHR-2017 after administration, including CL/F measure: The pharmacodynamic parameter of SHR-2017 after administration include uNTX/uCr measure: The pharmacodynamic parameter of SHR-2017 after administration include β-CTX measure: The pharmacodynamic parameter of SHR-2017 after administration include BALP [Time measure: Change from baseline in worst pain/average pain at the designated bone metastasis pain site after dosing measure: Incidence of skeletal-related event measure: Average daily total opioids consumption sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Cancer Hospital city: Beijing state: Beijing zip: 100142 country: China name: Huiping Li role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06380868 id: Nanjing-2 briefTitle: IVI-guided Versus Angiography-guided PCI in Patients With Diabetes Mellitus acronym: IVI-DIABETES overallStatus: ENROLLING_BY_INVITATION date: 2024-06-10 date: 2026-06-01 date: 2027-07-20 date: 2024-04-24 date: 2024-04-24 name: Nanjing First Hospital, Nanjing Medical University class: OTHER name: Shanxi Provincial People's Hospital briefSummary: Intravascular ultrasound (IVUS) serves as a beneficial instrument during percutaneous coronary intervention (PCI) procedures, affording insight into lesion characteristics and stent implantation. The ULTIMATE trial recently evidenced that IVUS-guided Drug-Eluting Stent (DES) implantation notably ameliorated clinical outcomes in all-comers, especially in patients who underwent an optimal procedure defined by IVUS, as opposed to angiography guidance, resonating with findings from the IVUS-XPL study, OCTOBER trial, and RENOVATE COMPLEX PCI trial, further confirmed by more recent IVUS-ACS trial.
Regrettably, a dearth of prospective, randomized, multicenter trials exists that scrutinize the benefits of IVI-guided as opposed to angiography-guided PCI in patients suffering from diabetes mellitus. However, several trials have presented subgroup analyses reporting the reduction of clinical events by IVUS but not OCT guidance in patients with diabetes mellitus, which served as the foundation for the design of this trial. conditions: Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients will undergo 1:1 randomization to either intravascular imaging (including intravascular ultrasound or optical coherence tomography)-guided DES implantation which will be the treatment group or Angio-guided DES implantation which will be the control group, stratified by research sites. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Randomization will be performed in the catheter laboratory by an invasive nurse. Staff in the catheter laboratory will be not blinded to the treatment allocation. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 1332 type: ESTIMATED name: Intravascular imaging-guided PCI name: Angiography-guided PCI group measure: Rate of target vessel failure (TVF) measure: Rate of target vessel failure without procedure-related MI measure: Rate of cardiac death measure: Rate of all-cause death measure: Rate of procedure-related myocardial infarction (PMI) measure: Rate of spontaneous myocardial infarction (SMI) measure: Rate of clinically-driven revascularization measure: Rate of stent thrombosis sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanjing First Hospital city: Nanjing state: Jiangsu zip: 210006 country: China lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06380855 id: GIHSYSU-34 briefTitle: Flexible Colonoscope Assisted Hybrid Transanal Total Mesorectal Resection (taTME) overallStatus: RECRUITING date: 2022-08-24 date: 2025-08-24 date: 2025-08-24 date: 2024-04-24 date: 2024-04-24 name: Sun Yat-sen University class: OTHER briefSummary: The investigators propose to use flexible endoscopy combined with transanal total mesorectal resection to further reduce anal injury. conditions: Rectal Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 5 type: ESTIMATED name: Flexible colonoscope assisted hybrid transanal total mesorectal resection measure: Success rate of operation sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Department of colorectal surgery, the Sixth Affiliated Hospital, Sun Yat-Sen University status: RECRUITING city: Guangzhou state: Guangdong zip: 510000 country: China name: Liang Kang, MD, PhD role: CONTACT phone: 008613602886833 email: eonkang@163.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06380842 id: 2023HX1970 briefTitle: Organ Dysfunction Change in Acute Necrotizing Pancreatitis Patients With Sepsis After Open Necrosectomy overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2026-12-30 date: 2026-12-30 date: 2024-04-24 date: 2024-04-24 name: Chunling Jiang class: OTHER briefSummary: The purpose of this study is to characterize organ dysfunction change in acute necrotizing pancreatitis patients with sepsis after open necrosectomy. conditions: Necrotizing Pancreatitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: Necrotizing Pancreatitis patients' organ dysfunction progression measure: Measure organ dysfunction change after open necrosectomy with respect to time measure: incidence of a composite of major complications measure: Incidence of ICU mortality measure: Incidence of hospital mortality measure: Incidence of 28-day mortality measure: Incidence of one year mortality measure: ICU length of hospital stay measure: Length of hospital stay measure: The pancreatic symptoms score measure: The levels of inflammatory factor CRP measure: The levels of inflammatory cytokines IL-6 measure: The levels of inflammatory procalcitonin sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06380829 id: Adnan Menderes briefTitle: Psychometric Properties of the Self-Care Assessment Scale for 3-6 Year Old Children With Cerebral Palsy-Parent Form overallStatus: COMPLETED date: 2023-06-05 date: 2023-12-05 date: 2024-02-10 date: 2024-04-24 date: 2024-04-24 name: Aydin Adnan Menderes University class: OTHER briefSummary: This study is a methodological study to develop the self-care assessment scale-parent form of children with CP aged 3-6 years and test its validity and reliability.
Q1. Is the Self-Care Assessment Scale for 3- to 6-year-old Children with CP a valid scale? Q2. Is the Self-Care Assessment Scale for 3- to 6-year-old Children with CP a reliable scale? conditions: Cerebral Palsy conditions: Self Care studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 127 type: ACTUAL name: Questionnaire measure: To asses Turkish validity and reliability of Self-Care Assessment Scale for Children with CP aged 3-6 years sex: ALL minimumAge: 3 Years maximumAge: 6 Years stdAges: CHILD facility: Bircan Kahraman Berberoğlu city: Aydın zip: 0900 country: Turkey lat: 37.84501 lon: 27.83963 hasResults: False
nctId: NCT06380816 id: CRUKD/24/001 id: ISRCTN26628699 type: REGISTRY domain: ISRCTN briefTitle: A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2029-11 date: 2029-11 date: 2024-04-24 date: 2024-04-24 name: Cancer Research UK class: OTHER name: UCB Biopharma SRL briefSummary: This clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody. It has been designed to work by targeting a protein called human leucocyte antigen G (HLA-G) that is found in high levels on some cancer cells. By attaching itself to this protein it may help the immune system to attack and kill the cancer cells.
4. Whether UCB4594 can cause cancer to shrink. conditions: Advanced Solid Tumours conditions: Squamous Cell Carcinoma of Head and Neck conditions: Carcinoma, Non-Small-Cell Lung conditions: Colorectal Neoplasms conditions: Triple Negative Breast Neoplasms conditions: Carcinoma, Renal Cell (Clear Cell Only) conditions: Esophageal Neoplasms conditions: Stomach Neoplasms (Excluding Gastrointestinal Stromal Tumors) conditions: Uterine Cervical Neoplasms conditions: Ovarian Neoplasms conditions: Pancreatic Neoplasms studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 167 type: ESTIMATED name: UCB4594 measure: Recommended Phase 2 dose (RP2D) of UCB4594 measure: Frequency of adverse events (AEs) considered at least possibly related to UCB4594 (up to 18 cycles). measure: Number of patients achieving a complete response (CR)/immune CR (iCR) or partial response (PR)/immune PR (iPR) to UCB4594 (all modules). measure: Maximum concentration of UCB4594 (monotherapy modules; Modules A and B). measure: Minimum concentration of UCB4594 (monotherapy modules; Modules A and B). measure: Area under the curve of UCB4594 (monotherapy modules; Modules A and B). measure: Steady state volume of distribution of UCB4594 (monotherapy modules; Modules A and B). measure: Clearance of UCB4594 (monotherapy modules; Modules A and B). measure: Frequency of AEs considered at least possibly related to UCB4594 (up to end of AE reporting period). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Christie NHS Foundation Trust city: Manchester country: United Kingdom name: Fiona Thistlethwaite, Prof role: CONTACT phone: +44 (0)161 9187672 email: fiona.thistlethwaite@nhs.net lat: 53.48095 lon: -2.23743 facility: University Hospital Southampton NHS Foundation Trust city: Southampton country: United Kingdom name: Ioannis Karydis, Prof role: CONTACT email: I.Karydis@soton.ac.uk lat: 50.90395 lon: -1.40428 hasResults: False
nctId: NCT06380803 id: 4-2020-1385 briefTitle: Surgical Skill Labs for Robotic Mastectomy and Educational Program Using a Surgical Guide by Artificial Intelligence acronym: ROMCAPO+AI overallStatus: RECRUITING date: 2021-04-29 date: 2025-01-26 date: 2025-01-26 date: 2024-04-24 date: 2024-04-24 name: Severance Hospital class: OTHER name: National Research Foundation of Korea briefSummary: The goal of this prospective study is to investigate the satisfaction, NASA-Task Load Index (TLX), and surgical proficiency of a robotic breast surgery education program using cadaver or porcine models, as well as to develop an AI-based surgical guide for utilization within the educational program in trainees for robotic breast surgery.
After the development of the surgical guide based on AI, researchers will compare a training group with or without surgical guide to see the effect of the surgical guide. conditions: Breast Neoplasms conditions: Surgery conditions: Educational Problems conditions: Surgical Procedure, Unspecified studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 64 type: ESTIMATED name: A educational program measure: Satisfaction questionnaire of a educational program measure: NASA-Task Load index of a educational program measure: Global Evaluative Assessment of Robotic Skills of a robotic breast surgery for surgical proficiency measure: The comparison of satisfaction questionnaire of a educational program between the group with the surgical guide and without the surgical guide measure: The comparison of NASA-Task Load index of a educational program between the group with the surgical guide and without the surgical guide measure: The comparison of Global Evaluative Assessment of Robotic Skills of a robotic breast surgery for surgical proficiency between the group with the surgical guide and without the surgical guide sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Yonsei University College of Medicine status: RECRUITING city: Seoul zip: 120-752 country: Korea, Republic of name: Hyung Seok Park, MD, PhD role: CONTACT phone: +82-2228-2100 email: imgenius@yuhs.ac lat: 37.566 lon: 126.9784 hasResults: False